February 14, 2018 / 6:48 PM / 10 months ago

FDA approves J&J prostate cancer treatment

Feb 14 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson’s Erleada treatment for use with prostate cancer patients whose cancer has not spread but continues to grow despite hormone therapy.

The drug is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer, the FDA said in a statement. (Reporting by Manas Mishra in Bengaluru; editing by Patrick Graham)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below